Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02635997

Enrollment

425

Registered

2015-12-21

Start date

2013-01-31

Completion date

2015-06-30

Last updated

2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Keywords

osteoporosis, ibandronate, vitamine D, calcium, bone mineral density, health-related quality of life

Brief summary

Ibandronate is a third-generation biphosphonate with recognized antiresorptive efficacy by several international, randomized, double-blind, controlled trials. These studies have not included patients from central america, to the best of our knowledge. Therefore, this open-label, uncontrolled study, was set out to assess the clinical effects of a 6-m treatment course with Ibandronate plus vitamine D and Calcium on bone mineral density and health-related quality of life.

Interventions

DRUGantiresorptive therapy

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women with a diagnosis of osteoporosis of at-Risk * Have a medical indication to receive Ibandronate+Vitamine D+Calcium

Exclusion criteria

* Osteoporosis due to secondary causes

Design outcomes

Primary

Measure	Time frame
Bone Mineral Density	6 months
Health-Related Quality of Life	6 months

Secondary

Measure	Time frame
Adverse Events	6 months

Countries

Argentina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026